- Membership Level
- Diamond Elite
- Company Headquarters
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a key growth platform for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in hematology.
By harnessing the power of four scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
New Normal, Same Cancer: Our Commitment to the Cancer Community During the Pandemic
Patient Assistance Programs
If you can’t afford your medicine, AstraZeneca may be able to help.
At AstraZeneca, we believe it’s not enough for us to simply make medicines. We have to help make sure that the people who need those medicines have access to them. It’s why we’ve offered patient assistance programs for more than 35 years.Learn More Here